avizakimab (BOS161721)
/ Boston Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 25, 2020
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
(clinicaltrials.gov)
- P1b/2; N=143; Completed; Sponsor: Boston Pharmaceuticals; Active, not recruiting ➔ Completed
Clinical • Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
August 30, 2020
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
(clinicaltrials.gov)
- P1b/2; N=143; Active, not recruiting; Sponsor: Boston Pharmaceuticals; Trial primary completion date: Aug 2020 ➔ Nov 2020
Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 2
Of
2
Go to page
1